AAISG 2024 Meeting

Buford, GA US
May 3, 2024 to May 5, 2024

The Allergy, Asthma, and Immunology Society of Georgia's 2024 Meeting offers Allergists/Immunologists the opportunity to learn new techniques and treatments to provide better patient care using the saftest, most proven therapies presented by leaders in their field. AAISG also seeks to provide assistance in practice management to aid in the care of patients.

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and the Allergy Asthma & Immunology Society of Georgia (AAISG).  The American College of Allergy, Asthma and Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 7.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience

Practicing allergists
Primary care physicians
Allied healthcare professionals

Learning Objectives

At the conclusion of this Activity learners should be able to…

1. Identify patients where genetic testing is indicated.
2. Interpret the results of genetic testing.
3. Choose the appropriate biologic therapy for allergic and immunologic diseases.
4. Manage the patient who previously has recovered from COVID infection. 

Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma & Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies. Examples of ineligible companies include:

•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All relevant financial relationships with ineligible companies have been mitigated.

Course summary
Available credit: 
  • 7.50 AMA PRA Category 1 Credit™
  • 7.50 Attendance
Course opens: 
05/03/2024
Course expires: 
12/31/2025
Event starts: 
05/03/2024 - 6:00pm CDT
Event ends: 
05/05/2024 - 12:30pm CDT
Rating: 
0

2024 Allergy, Asthma & Immunology Society of Georgia Meeting Agenda

Friday, May 3, 2024   
6:00 pm – 7:00 pm    Cocktails and Registration (non-CME)    
7:00 pm – 8:00 pm    Betty Wray Lecture and Dinner: Asthma and Biotherapeutics, Lanny Rosenwasser, MD     
8:00 pm – 9:00 pm    Social Networking Time (non-CME)    

Saturday, May 4, 2024
7:00 am – 8:00 am    Breakfast (Non-CME)    
8:00 am – 9:00 am    Biotherapeutics and Anti-Cytokines in Allergic Disease, Lanny Rosenwasser, MD     
9:00 am – 9:20 am    Food Protein-Induced Enterocolitis to Peanut, Jessica Feng, MD, MPH    
9:20 am – 9:40 am    Persistent Hypogammaglobulinemia Following Rituximab in a Cohort of Pediatric Patients, Jennifer Xu, MD    
9:40 am – 10:00 am    Break (non-CME)    
10:00 am – 11:00 am    Food Allergy 2024: Where Do We Go From Here Part 1, Christine Ciaccio, MD    
11:00 am – 12:00 pm    Food Allergy 2024: Where Do We Go From Here Part 2, Christine Ciaccio, MD    
12:00 pm – 12:30 pm    GINA Guideline Updates (Brief Overview from ACAAI), Kathleen May, MD (non-CME)    
12:30 pm – 1:00 pm    Business Meeting (All members encouraged to attend) (non-CME)    
12:30 pm – 1:30 pm    Lunch (non-CME)    
7:30 pm – 10:00 pm    Dinner and Entertainment (non-CME)    

Sunday, May 5, 2024
7:00 am – 8:00 am    Breakfast (non-CME)    
8:00 am – 9:00 am    Buy and Bill for Biologics: The Risks and Rewards, Jennifer Kuehn, CPC    
9:00 am – 9:20 am     A Case of Sever Eczema, Amanda Hall, MD    
9:20 am – 9:40 am    An Adolescent with Hypereosinophilia, Tyesha Coleman    
9:40 am – 10:00 am    Break (non-CME)    
10:00 am – 11:00 am    Putting the AI in A/I, Sakina Bajowala, MD    
11:00 am – 11:30 am    Lunch (non-CME)    
11:30 am – 12:30 pm    (non-CME Presentation)    
12:30pm    Adjourn

Lanier Islands Legacy Lodge
7000 Lanier Islands Parkway
Buford, GA 30518
United States

All identified relevant financial relationships with ineligible companies have been mitigated.

Christina Ciaccio, MD, Speaker
Consultant:  Clostrabio, Siolta
Stocks/Stock Options: Clostrabio, Siolta
Advisor: Genentech
Speaker: Genentech

Sakina Bajowala, MD, Speaker
Advisor - Novartis, ARS Pharma
Ownership Interest: Wise Prince, LLC

The following have no relevant financial relationships with ineligible companies to disclose:
Rodney Johnson, MD, Planner
Julie Ellerbee, Planner
Amanda Hall, MD, Speaker
Jessica Feng, MD, Speaker
Jennifer Kuehn, Speaker
Jennifer Xu, MD, Speaker
Lanny Rosenwasser, MD, Speaker
Tyesha Coleman, MD, Speaker

Available Credit

  • 7.50 AMA PRA Category 1 Credit™
  • 7.50 Attendance
Please login or create an account to take this course.